Curtis Ruegg, EVP R&D and Technology Operations at Revance Therapeutics, Inc. (RVNC), sold 2,000 shares at $20.50 ($41K) on 2014-09-17, disclosed to the SEC on 2014-09-19.
Scheduled sale ($41k) by EVP R&D and Technology Operations under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.50 | 162 | $3K | 8.1% |
| 2 | $20.51 | 500 | $10K | 25.0% |
| 3 | $20.56 | 500 | $10K | 25.0% |
| 4 | $20.57 | 838 | $17K | 41.9% |
| Total | $20.55 avg | 2,000 | $41K | 100% |
| Filing → |
| RVNC | SELL | 2016-04-13 | $19K | — | Filing → |
| RVNC | SELL | 2016-03-09 | $20K | — | Filing → |
| RVNC | SELL | 2016-02-10 | $18K | — | Filing → |